CY2576B1 - Vitronectin receptor antagonists - Google Patents

Vitronectin receptor antagonists

Info

Publication number
CY2576B1
CY2576B1 CY0700010A CY0700010A CY2576B1 CY 2576 B1 CY2576 B1 CY 2576B1 CY 0700010 A CY0700010 A CY 0700010A CY 0700010 A CY0700010 A CY 0700010A CY 2576 B1 CY2576 B1 CY 2576B1
Authority
CY
Cyprus
Prior art keywords
receptor antagonists
vitronectin receptor
vitronectin
antagonists
receptor
Prior art date
Application number
CY0700010A
Other languages
English (en)
Inventor
James Francis Callahan
Russel Donovan Cousins
Richard Mccullock Keenan
Chet Kwon
William Henry Miller
Irene Nijole Uzinkas
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of CY2576B1 publication Critical patent/CY2576B1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CY0700010A 1996-10-02 2007-05-18 Vitronectin receptor antagonists CY2576B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2732096P 1996-10-02 1996-10-02
US4377697P 1997-04-11 1997-04-11

Publications (1)

Publication Number Publication Date
CY2576B1 true CY2576B1 (en) 2008-07-02

Family

ID=26702318

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0700010A CY2576B1 (en) 1996-10-02 2007-05-18 Vitronectin receptor antagonists

Country Status (36)

Country Link
EP (1) EP0957917B1 (pl)
JP (2) JP4491072B2 (pl)
KR (1) KR100589578B1 (pl)
CN (1) CN1114403C (pl)
AP (1) AP1463A (pl)
AR (1) AR008878A1 (pl)
AT (1) ATE312089T1 (pl)
AU (1) AU733417B2 (pl)
BG (1) BG64581B1 (pl)
BR (1) BR9712248B1 (pl)
CA (1) CA2267224C (pl)
CO (1) CO4900046A1 (pl)
CY (1) CY2576B1 (pl)
CZ (1) CZ299076B6 (pl)
DE (1) DE69734833T2 (pl)
DK (1) DK0957917T3 (pl)
DZ (1) DZ2320A1 (pl)
EA (1) EA002419B1 (pl)
ES (1) ES2252775T3 (pl)
HU (1) HU229221B1 (pl)
ID (1) ID19623A (pl)
IL (1) IL129243A (pl)
MA (1) MA24361A1 (pl)
MY (1) MY137606A (pl)
NO (1) NO320194B1 (pl)
NZ (1) NZ334953A (pl)
PE (1) PE10499A1 (pl)
PL (1) PL190859B1 (pl)
RO (1) RO119881B1 (pl)
SA (1) SA98180936B1 (pl)
SK (1) SK285029B6 (pl)
TR (1) TR199900737T2 (pl)
TW (1) TW487702B (pl)
UA (1) UA60311C2 (pl)
UY (2) UY24735A1 (pl)
WO (1) WO1998014192A1 (pl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
WO1999015178A1 (en) * 1997-09-24 1999-04-01 Smithkline Beecham Corporation Vitronectin receptor antagonist
AU9577498A (en) * 1997-09-24 1999-04-12 Smithkline Beecham Corporation Vitronectin receptor antagonist
US6372719B1 (en) 1998-03-04 2002-04-16 Jay Cunningham ανβ3 integrin antagonists in combination with chemotherapeutic agents
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
CN1398189A (zh) * 1998-12-23 2003-02-19 G.D.西尔公司 用于治疗肿瘤形成的放疗与cox-2抑制剂的联合治疗
EP1150965A4 (en) * 1999-02-03 2002-05-15 Merck & Co Inc BENZAZEPINE DERIVATIVES AS ALPHA-V INTGRIN RECEPTOR ANTAGONISTS
ATE433752T1 (de) * 1999-04-30 2009-07-15 Univ Michigan Verwendung von benzodiazepinen zur behandlung von autoimmunischen krankheiten, entzündungen, neoplasien, viralen infektionen und atherosklerosis
EP1208101A4 (en) * 1999-08-06 2003-03-19 Smithkline Beecham Corp VITRONECTIN RECEPTOR ANTAGONISTS USEFUL FOR THE TREATMENT OF VASCULAR ACCIDENTS
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
DE10027514A1 (de) * 2000-06-06 2002-01-03 Basf Ag Liganden von Integrinrezeptoren
DE10028575A1 (de) 2000-06-14 2002-03-14 Basf Ag Integrinliganden
FR2806082B1 (fr) * 2000-03-07 2002-05-17 Adir Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
NZ539682A (en) 2001-01-29 2006-03-31 Dimensional Pharm Inc Substituted indoles and their use as integrin antagonists
BR0208789A (pt) * 2001-04-10 2004-03-09 Smithkline Beecham Corp Método para inibição da formação de adesão
SE0101386D0 (sv) 2001-04-20 2001-04-20 Astrazeneca Ab New compounds
CA2445679A1 (en) * 2001-05-03 2002-11-14 Paul J. Coleman Benzazepinone alpha v integrin receptor antagonists
WO2003059251A2 (en) 2001-10-22 2003-07-24 The Scripps Research Institute Antibody targeting compounds
GB0215867D0 (en) * 2002-07-09 2002-08-14 Glaxosmithkline Spa Novel method and compounds
US7368566B2 (en) * 2003-04-04 2008-05-06 Smithkline Beecham Corporation Process and intermediates for preparing benzazepines
PL1734996T3 (pl) * 2004-04-02 2013-09-30 Univ California Sposoby i kompozycje do leczenia i profilaktyki choroby związanej z integryną alfa v beta 5
AU2012216372B2 (en) * 2004-04-02 2015-01-22 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
AR052823A1 (es) * 2004-12-21 2007-04-04 Smithkline Beecham Corp Uso de un antagonista del receptor de vitronectina para l a preparacion de una formulacion farmaceutica util para inhibir el exceso de formacion de cicatrices en la piel de a un mamifero y dicha formulacion
PL1968594T3 (pl) * 2005-11-29 2011-03-31 Glaxosmithkline Llc Leczenie zaburzeń neowaskularyzacyjnych oka, takich jak zwyrodnienie plamki żółtej, rozszerzenie naczyń siatkówki w zespole Hippla i Lindaua, zapalenie błony naczyniowej oka i obrzęk plamki
US9345739B2 (en) 2007-11-08 2016-05-24 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
AU2008321770B2 (en) * 2007-11-16 2012-09-06 Ube Industries, Ltd. Benzazepinone compound
US8076475B2 (en) * 2008-03-06 2011-12-13 Glaxosmithkline Llc Process
WO2010093706A2 (en) 2009-02-10 2010-08-19 The Scripps Research Institute Chemically programmed vaccination
WO2010113958A1 (ja) 2009-03-30 2010-10-07 宇部興産株式会社 眼の疾患の治療又は予防のための医薬組成物
JP5572996B2 (ja) * 2009-05-15 2014-08-20 宇部興産株式会社 ベンズアゼピノン化合物を有効成分として含有する医薬
CA2767409C (en) 2009-07-24 2018-10-30 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with .alpha.v.beta.5 integrin
EP2501387B1 (en) 2009-11-17 2016-07-27 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
EP2325194A1 (en) * 2009-11-24 2011-05-25 Glycotope GmbH Process for the purification of glycoproteins
ES2864079T3 (es) 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
BR112022021228A2 (pt) * 2020-04-26 2022-12-06 Jiangsu Nhwa Pharmaceutical Co Ltd Derivado da 1,5-di-hidro-2,4-benzodiazepin-3-ona e aplicação do mesmo
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG63579A1 (en) * 1992-12-21 1999-03-30 Smithkline Beecham Corp Bicyclic fibrinogen antagonists
ZA955391B (en) * 1994-06-29 1996-02-09 Smithkline Beecham Corp Vitronectin receptor antagonists
AU702661B2 (en) * 1994-06-29 1999-02-25 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO1996006087A1 (en) * 1994-08-22 1996-02-29 Smithkline Beecham Corporation Bicyclic compounds
WO1996026190A1 (en) * 1995-02-22 1996-08-29 Smithkline Beecham Corporation Integrin receptor antagonists
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція

Also Published As

Publication number Publication date
SK42599A3 (en) 1999-12-10
KR20000048816A (ko) 2000-07-25
TW487702B (en) 2002-05-21
EP0957917A1 (en) 1999-11-24
HK1023730A1 (en) 2000-09-22
IL129243A0 (en) 2000-02-17
JP2010006838A (ja) 2010-01-14
EA002419B1 (ru) 2002-04-25
WO1998014192A1 (en) 1998-04-09
AU4746297A (en) 1998-04-24
DE69734833D1 (de) 2006-01-12
UY24735A1 (es) 1998-03-30
BR9712248A (pt) 1999-08-24
SA98180936B1 (ar) 2006-05-30
EA199900356A1 (ru) 2000-02-28
CA2267224C (en) 2007-03-13
CZ113299A3 (cs) 2000-03-15
PL190859B1 (pl) 2006-02-28
JP2001501936A (ja) 2001-02-13
HU229221B1 (en) 2013-09-30
UY24935A1 (es) 2001-07-31
NO991590D0 (no) 1999-03-31
NO320194B1 (no) 2005-11-14
HUP9903769A2 (hu) 2000-03-28
UA60311C2 (uk) 2003-10-15
BG103299A (en) 2000-01-31
TR199900737T2 (xx) 1999-07-21
DK0957917T3 (da) 2006-04-18
NO991590L (no) 1999-05-31
CN1114403C (zh) 2003-07-16
PL332674A1 (en) 1999-09-27
EP0957917B1 (en) 2005-12-07
JP4491072B2 (ja) 2010-06-30
EP0957917A4 (en) 2002-05-15
RO119881B1 (ro) 2005-05-30
AP1463A (en) 2005-09-10
DE69734833T2 (de) 2006-07-13
CA2267224A1 (en) 1998-04-09
IL129243A (en) 2004-07-25
BG64581B1 (bg) 2005-08-31
MY137606A (en) 2009-02-27
AP9901493A0 (en) 1999-03-31
DZ2320A1 (fr) 2002-12-28
ATE312089T1 (de) 2005-12-15
SK285029B6 (sk) 2006-04-06
CO4900046A1 (es) 2000-03-27
ID19623A (id) 1998-07-23
NZ334953A (en) 2000-01-28
CZ299076B6 (cs) 2008-04-16
MA24361A1 (fr) 1998-07-01
PE10499A1 (es) 1999-03-27
BR9712248B1 (pt) 2010-06-29
AR008878A1 (es) 2000-02-23
ES2252775T3 (es) 2006-05-16
CN1238689A (zh) 1999-12-15
HUP9903769A3 (en) 2000-07-28
KR100589578B1 (ko) 2006-06-15
AU733417B2 (en) 2001-05-17

Similar Documents

Publication Publication Date Title
IL129243A0 (en) Vitronectin receptor antagonists
EP0767792A4 (en) VITRONECTIN RECEPTOR ANTAGONISTS
ZA955391B (en) Vitronectin receptor antagonists
IL125030A0 (en) Vitronectin receptor antagonists
IL125033A0 (en) Vitronectin receptor antagonists
IL125034A0 (en) Vitronectin receptor antagonists
ZA9896B (en) Vitronectin receptor antagonists
EP1000031A4 (en) VITRONECTIN RECEPTOR ANTAGONISTS
IL135189A0 (en) Vitronectin receptor antagonist
IL135028A0 (en) Vitronectin receptor antagonists
IL138245A0 (en) Vitronectin receptor antagonists
IL135188A0 (en) Vitronectin receptor antagonist
PL346157A1 (en) Vitronectin receptor antagonists
SI0957917T1 (sl) Antagonisti receptorja vitronektina
ZA988562B (en) Vitronectin receptor antagonists
ZA978798B (en) Vitronectin receptor antagonists.
GB9815803D0 (en) Vitronectin receptor antagonists
GB9810182D0 (en) Vitronectin receptor antagonists
GB9810882D0 (en) Vitronectin receptor antagonists
GB9807382D0 (en) Vitronectin receptor antagonists
GB9811295D0 (en) Vitronectin receptor antagonists
GB9810892D0 (en) Vitronectin receptor antagonists
GB9807384D0 (en) Vitronectin receptor antagonists
GB9822331D0 (en) Vitronectin receptor antagonists
GB9812686D0 (en) Vitronectin receptor antagonists